ProPhase Labs, Inc. Effective Income Tax Rate Reconciliation, Nondeductible Expense, Percent
ProPhase Labs, Inc. (PRPH) reported Effective Income Tax Rate Reconciliation, Nondeductible Expense, Percent of -1.10% for the 12-month period ending 2025-12-31, per its 10-K filed 2026-06-01.
Financial Statements › Expense Statement › Income Tax
us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense · last filed 2026-06-01
- ProPhase Labs, Inc. effective income tax rate reconciliation, nondeductible expense, percent for fiscal 2025 was -1.10%.
- ProPhase Labs, Inc. effective income tax rate reconciliation, nondeductible expense, percent for fiscal 2024 was 0.00%.
| Period end | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Percent 12 month |
|---|---|
| 2025-12-31 | -1.10% 10-K · filed 2026-06-01 |
| 2024-12-31 | 0.00% 10-K · filed 2026-06-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Xenetic Biosciences, Inc. (XBIO) | United States | $0.006B | |
| Processa Pharmaceuticals, Inc. (PCSA) | United States | $0.005B | |
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| Ernexa Therapeutics Inc. (ERNA) | United States | $0.006B | |
| Dermata Therapeutics, Inc. (DRMA) | United States | $0.005B | -0.62 |
| REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH) | United States | $0.005B | |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |
| Cadrenal Therapeutics, Inc. (CVKD) | United States | $0.004B | -0.90 |
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |